Molecular structure of S(−)-Carbidopa, CAS Number: 38821-49-7
S(-)-Carbidopa (CAS 38821-49-7)
Alternate Names:
D,L-Carbidopa
Application:
S(−)-Carbidopa is a DDC (dopa decarboxylase) inhibitor
CAS Number:
38821-49-7
Purity:
≥95%
Molecular Weight:
226.23
Molecular Formula:
C10H14N2O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
S(−)-Carbidopa is an inhibitor of peripheral decarboxylase, the enzyme responsible for conversion of L-DOPA to dopamine. Administration of S(−)-Carbidopa with L-DOPA demonstrates a decrease in the effects associated with rapid conversion of L-DOPA to dopamine. S(−)-Carbidopa is also demonstrated to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.
S(-)-Carbidopa (CAS 38821-49-7) References
- Intravenous l-DOPA plus carbidopa in depressed patients: average evoked response, learning, and behavioral changes. | Henry, GM., et al. 1976. Psychosom Med. 38: 95-105. PMID: 1273240
- The impact of levodopa on quality of life in patients with Parkinson disease. | Sethi, KD. 2010. Neurologist. 16: 76-83. PMID: 20220441
- Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease. | Hoy, SM. 2019. Drugs. 79: 1709-1718. PMID: 31549300
- Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis. | Liao, X., et al. 2020. Neurol Sci. 41: 2045-2054. PMID: 32162166
- Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. | Rosebraugh, M., et al. 2021. Ann Neurol. 90: 52-61. PMID: 33772855
- Symptomatic use of carbidopa in autonomic disorders. | Golden, EP., et al. 2021. Auton Neurosci. 236: 102888. PMID: 34610497
- Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα. | Chen, Z., et al. 2022. Invest New Drugs. 40: 1216-1230. PMID: 36070108
- Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson's disease: is it an improvement on other delivery? | Doggrell, SA. 2023. Expert Opin Drug Deliv. 20: 1189-1199. PMID: 37634938
- The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. | Deleu, D., et al. 1993. Naunyn Schmiedebergs Arch Pharmacol. 348: 576-81. PMID: 8133901
- Levodopa/carbidopa for childhood amblyopia. | Leguire, LE., et al. 1993. Invest Ophthalmol Vis Sci. 34: 3090-5. PMID: 8407216
Inhibitor of:
DDC, and Monoamine Oxidase.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
S(-)-Carbidopa, 5 g | sc-361978 | 5 g | $500.00 |